By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Gyre Therapeutics, Inc. company insiders have only been selling lately: two insiders trimmed about $953,000 of stock over 12 months, with no open-market purchases.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. Big money check: 60 institutions held GYRE as of Q2 2026, and more funds bought than sold.
Are insiders buying or selling GYRE stock?
In the last 12 months Gyre Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $953,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in GYRE?
The most recent open-market insider trade in GYRE was filed on 2026-06-22.
How many institutions own GYRE?
60 investment managers reported holding GYRE in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded GYRE?
No congressional trades in GYRE were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).